Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
More Pharma, R&D for Lonza
September 19, 2005
| A version of this story appeared in
Volume 83, Issue 38
Lonza will expand capacity for active pharmaceutical ingredients in Visp, Switzerland. A $20 million first phase, to be completed during 2006, will include a new building and enlarged drying capacity. The firm later plans two production trains for final products and up to three drying trains. Separately, the company is building a new R&D center in Nansha near Guangzhou, China. The center, to house about 60 scientific personnel, is expected to open in the first quarter of next year. An existing R&D group in Guangzhou will relocate there.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter